Hyzaar News
cozaar, Brand and Generic - Cheap Prices. - Fatman Games
Hyzaar 100 mg once daily. Order up now. As a good, help to the developing foetus. Angiotensin formed in the artery to a is a remarkable drug. ...
2ND UPDATE: Merck Posts 4th-Quarter Loss On Charges Tied To Vioxx ... - EasyBourse.com
Older hypertension medicines Cozaar and Hyzaar saw sales rise 3% to $891 million. Another best-selling product, the osteoporosis drug Fosamax, ...
Merck Posts $1.6 Billion Q4 Loss - Washington Post
Sales jumped 20 percent for Singulair, to $1.15 billion, and rose 3 percent, to $891 million, for related blood pressure drugs Cozaar and Hyzaar. ...
Irving Kahn Buys MBIA Inc., Old Republic International Corp., The ... - GuruFocus.com
It offers Singulair for treating asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar and Vasotec etc. Merck & Co. ...
Merck Posts $1.6 Billion Q4 Loss - The Associated Press
Sales jumped 20 percent for Singulair, to $1.15 billion, and rose 3 percent, to $891 million, for related blood pressure drugs Cozaar and Hyzaar. ...
Merck Announces 2007 Financial Results Reflecting Revenue Growth ... - PharmaLive.com (press release)
Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR(2) , were $891 million for the fourth quarter of 2007, a 3 percent increase compared ...
Merck's Fosamax gets the ax - CNNMoney.com
Merck faces with its next big patent expiration in 2010, when the $3 billion-a-year Cozaar/Hyzaar hypertension franchise loses protection. ...
Edward Owens Buys Sepracor Inc., PDL BioPharma Inc., Walgreen ... - GuruFocus.com
It offers Singulair for treating asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar etc. Merck & Co. Inc. has a market cap of $99.52 billion ...
Earnings Preview: Merck & Co. - Forbes
... sales to $1.1 billion in the quarter, and a 1 percent increase in sales of the hypertension drugs Cozaar and Hyzaar to $870 million during the quarter. ...
Merck's Patent On Blockbuster Osteoporosis Drug Fosamax Runs Out - Therapeutics Daily (subscription) (press release)
... Fosamax has run out and faces its next big patent expiration in 2010, when the $3 billion-a-year Cozaar/Hyzaar hypertension franchise loses protection. ...
Hyzaar RSS Feed